David Urech (file photo)

Mit­subishi joins Ei­sai, 3SBio's bet on mul­ti­spe­cif­ic an­ti­bod­ies, up­ping Num­ab's Se­ries B haul to $23M+

Fol­low­ing a busy year of deal­mak­ing, Swiss an­ti­body shop Num­ab has closed a Se­ries B at CHF22 mil­lion ($23.87 mil­lion) to dou­ble down on its mul­ti­spe­cif­ic mol­e­cules for im­muno-on­col­o­gy and grow its team.

The bulk of the cash comes from fa­mil­iar names. Chi­na’s 3SBio al­ready com­mit­ted CHF15 mil­lion ($15.2 mil­lion) when its sub­sidiary Sun­shine Guo­jian signed on­to a re­gion­al de­vel­op­ment and com­mer­cial­iza­tion deal late last year. Ei­sai, which is in for a dis­cov­ery pact, chipped in along­side Mit­subishi UFJ Cap­i­tal and Daniel Vasel­la — the for­mer CEO of No­var­tis and a Num­ab board mem­ber.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.